ReviewNutrients2025
Dietary Fatty Acids Modulate Gut Microbiota-Derived Trimethylamine-N-Oxide: Potential Mechanisms and Future Perspective.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review.Current allergy and asthma reports · 2026Pooled it
- The Gut Microbiota-Metabolite-Host Axis in Cardiometabolic Diseases: Bridging Bench to Bedside.Cardiovascular drugs and therapy · 2026Review
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Gut microbiota in chronic kidney disease-mineral and bone disorder: shared mechanisms, disease-specific signatures, and therapeutic prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-fat diets are known to contribute to metabolic disorders such as obesity, diabetes, and cardiovascular diseases, partly through alterations in gut microbiota composition. However, the impact of dietary fat on gut microbiota depends on fat composition, with both the degree of saturation and chain length of fatty acids playing essential roles in modulating microbial populations. Saturated long-chain fatty acids have been shown to promote the production of trimethylamine (TMA), a precursor of trimethylamine N-oxide (TMAO), an emerging gut microbiota-derived biomarker associated with cardiovascular disease. These effects occur through multiple mechanisms, including increased colonic oxygen levels and taurine-conjugated bile acids, which promote pathways that favor TMA-producing bacteria. In contrast, short-chain fatty acids (SCFAs) and omega-3 polyunsaturated fatty acids exert beneficial effects by altering pH and supporting SCFA-producing bacteria, thereby reducing levels of TMA-producing bacteria. Given the influence of gut microbial communities and their metabolites on the onset of metabolic disorders, dietary strategies that modulate the microbiota and its metabolic products through optimized fatty acid composition represent promising therapeutic approaches for preventing conditions such as cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.